No quarterly revenue total was found in XBiotech Inc.'s SEC filings.
XBiotech Inc. (XBIT) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$4.5 million.
Revenue
—
Net income
$-6.73M
-283.1% vs year-ago quarter
Operating cash flow
$-4.51M
+24.6% vs year-ago quarter
Free cash flow
$-4.51M
+25.2% vs year-ago quarter
EPS
—
Dividend per share
None
Shares outstanding
30.49M
+0.0% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XBIT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1626878
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$6.1M | -$6.3M | -$29.8M | -$6.0M | -$6.3M |
| Net income | -$6.7M | -$5.5M | -$26.9M | -$6.0M | -$1.8M |
| Operating cash flow | -$4.5M | -$9.0M | -$23.0M | -$4.3M | -$6.0M |
| Free cash flow | -$4.5M | -$9.0M | -$23.0M | -$4.4M | -$6.0M |
| Total assets | $133.7M | $139.8M | $150.1M | $172.4M | $178.7M |
| Total liabilities | $5.2M | $4.8M | $9.7M | $5.3M | $5.6M |
| Stockholders' equity | $128.5M | $135.0M | $140.3M | $167.1M | $173.1M |
| Cash and investments | $109.5M | $115.5M | $125.6M | $147.4M | $152.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 26, 2026 | Oct 23, 2026 |
| ARS | Annual report to shareholders | Oct 2, 2026 | Oct 2, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 10-K/A | Amended annual report | Apr 29, 2026 | Dec 31, 2025 |
| 10-K | Annual report | Mar 13, 2026 | Dec 31, 2025 |
All 407 XBiotech Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.